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Abstract
The CDC Vaccine Safety Datalink project has pioneered the use of
near real-time post-market vaccine safety surveillance for the rapid de-
tection of adverse events. Doing weekly analyses, continuous sequen-
tial methods are used, allowing investigators to evaluate the data near-
continuously while still maintaining the correct overall alpha level.
With continuous sequential monitoring, the null hypothesis may be
rejected after only one or two adverse events are observed. In this
paper, we explore continuous sequential monitoring when we do not
allow the null to be rejected until a minimum number of observed
events have occurred. We also evaluate continuous sequential analy-
sis with a delayed start until a certain sample size has been attained.
Tables with exact critical values, statistical power and the average
times to signal are provided. We show that, with the first option, it
is possible to both increase the power and reduce the expected time
to signal, while keeping the alpha level the same. The second option
is only useful if the start of the surveillance is delayed for logistical
reasons, when there is a group of data available at the first analysis,
followed by continuous or near-continuous monitoring thereafter.
Keywords: Drug safety; Pharmacovigilance; Continuous sequential analy-
sis; Surveillance; Sequential probability ratio test.
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1 Introduction
Post-market drug and vaccine safety surveillance is important in order to
detect rare but serious adverse events not found during pre-licensure clinical
trials. Safety problems may go undetected either because an adverse reaction
is too rare to occur in sufficient numbers among the limited sample size
of a phase three clinical trial, or because the adverse reaction only occur
in a certain sub population that was excluded from the trial, such as frail
individuals.
In order to detect a safety problem as soon as possible, the CDC Vaccine
Safety Datalink project pioneered the use of near real-time safety surveillance
using automated weekly data feeds from electronic health records[1, 2, 3]. In
such surveillance, the goal is to detect serious adverse reactions as early as
possible without too many false signals. It is then necessary to use sequential
statistical analysis, which adjusts for the multiple testing inherent in the
many looks at the data. Using the maximized sequential probability ratio
test (MaxSPRT)[4], all new childhood vaccines and some adult vaccines are
now monitored in this fashion[1, 5, 6, 7, 8, 9, 10, 11, 12, 13]. There is also
interest in using sequential statistical methods for post-market drug safety
surveillance[14, 15, 16, 17, 18, 19], and the methods presented in this paper
may also be used in either settings.
In contrast to group sequential analyses, continuous sequential methods
can signal after a single adverse event, if that event occurs sufficiently early.
In some settings, such as a phase 2 clinical trial, that may be appropriate, but
in post-market safety surveillance it is not. In post-market vaccine surveil-
lance, an ad-hoc rule that require at least two or three events to signal has
sometimes been used, but that leads to a conservative type 1 error (alpha
level). In this paper we provide exact critical values for continues sequential
analysis when a signal is required to have a certain minimum number of ad-
verse events. We also evaluate power and expected time to signal for various
alternative hypotheses. It is shown that it is possible to simultaneously im-
prove both of these by requiring at least 3 or 4 events to signal. Note that it
is still necessary to start surveillance as soon as the first few individuals are
exposed, since they all could have the adverse event.
For logistical reasons, there is sometimes a delay in the start of post-
marketing safety surveillance, so that the first analysis is not conducted until
a group of people have already been exposed to the drug or vaccine. This
is not a problem when using group sequential methods, as the first group is
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then simply defined to correspond to the start of surveillance. For continuous
sequential surveillance, a delayed start needs to be taken into account when
calculating the critical values. In this paper, we present exact critical values
when there is a delayed start in the sequential analysis. We also calculate
the power and time to signal for different relative risks.
In addition to ensuring that the sequential analysis maintains the correct
overall alpha level, it is important to consider the statistical power to reject
the null hypothesis; the average time until a signal occurs when the null
hypothesis is rejected; and the final sample size when the null hypothesis is
not rejected. For any fixed alpha, there is a trade-off between these three
metrics, and the trade-off depends on the true relative risks. In clinical trials,
where sequential analyses are commonly used, statistical power and the final
sample size are usually the most important design criteria. The latter is
important because patient recruitment is costly. The time to signal is usually
the least important, as a slight delay in finding an adverse event only affects
the relatively small number of patients participating in the clinical trial, but
not the population-at-large. In post-market safety surveillance, the trade-
off is very different. Statistical power is still very important, but once the
surveillance system is up and running, it is easy and cheap to prolong the
length of the study by a few extra months or years to achieve a final sample
size that provides the desired power. Instead, the second most critical metric
is the time to signal when the null is rejected. Since the product is already in
use by the population-at-large, most of which are not part of the surveillance
system, a lot of people may be spared the adverse event if a safety problem
can be detected a few weeks or months earlier. This means that for post-
market vaccine and drug safety surveillance, the final sample size when the
null is not rejected is the least important of the three metrics.
All calculations in this paper are exact, and none are based on simu-
lations or asymptotic statistical theory. The numerical calculation of the
exact critical values is a somewhat cumbersome process. So that users do
not have to do these calculations themselves, we present tables with exact
critical values for a wide range of parameters. For other parameters, we
have developed the open source R package ’Sequential’, freely available at
’cran.r-project.org/web/packages/Sequential’.
3
2 Continuous Sequential Analysis for Poisson
Data
Sequential analysis was first developed by Wald[20, 21], who introduced the
sequential probability ratio test (SPRT) for continuous surveillance. The
likelihood based SPRT proposed by Wald is very general in that it can be
used for many different probability distributions. The SPRT is very sensitive
to the definition of the alternative hypothesis of a particular excess risk. For
post-market safety surveillance, a maximized sequential probability ratio test
with a composite alternative hypothesis has often been used instead. This
is both a ‘generalized sequential probability ratio test’[22] and ‘sequential
generalized likelihood ratio test’[23, 24]. In our setting, it is defined as follows,
using the Poisson distribution to model the number of adverse events seen[4].
Let Ct be the random variable representing the number of adverse events
in a pre-defined risk window from 1 to W days after an incident drug dis-
pensing that was initiated during the time period [0, t]. Let ct be the cor-
responding observed number of adverse events. Note that time is defined in
terms of the time of the drug dispensing rather than the time of the adverse
event, and that hence, we actually do not know the value of ct until time
t+W .
Under the null hypothesis (H0), Ct follows a Poisson distribution with
mean µt, where µt is a known function reflecting the population at risk.
In our setting, µt reflects the number of people who initiated their drug
use during the time interval [0, t] and a baseline risk for those individuals,
adjusting for age, gender and any other covariates of interest. Under the
alternative hypothesis (HA), the mean is instead RRµt, where RR is the
increased relative risk due to the drug/vaccine. Note that C0 = c0 = µ0 = 0.
For the Poisson model, the MaxSPRT likelihood ratio based test statistic
is
LRt = max
HA
P (Ct = ct|HA)
P (Ct = ct|H0) = maxRR>1
e−RRµt(RRµt)ct/ct!
e−µtµctt /ct!
= max
RR>1
e(1−RR)µt(RR)ct
The maximum likelihood estimate of RR is ct/µt, so
LRt = e
µt−ct(ct/µt)ct
Equivalently, when defined using the log likelihood ratio
LLRt = ln(LRt) = max
RR>1
((1−RR)µt + ctln(RR)) = (µt − ct) + ctln(ct/µt)
4
This test statistic is sequentially monitored for all values of t > 0, until
either LLRt ≥ CV , in which case the null hypothesis is rejected, or until
µt = T , in which case the alternative hypothesis is rejected. T is a prede-
fined upper limit on the length of surveillance, defined in terms of the sample
size, expressed as the expected number of adverse events under the null hy-
pothesis. It is roughly equivalent to a certain number of exposed individuals,
but adjusted for covariates. Exact critical values (CV) are available for the
MaxSPRT[4], obtained through iterative numerical calculations.
3 Minimum Number of Events Required to
Signal
Continuous sequential probability ratio tests may signal at the time of the
first event, if that event appears sufficiently early. One could add a require-
ment that there need to be a minimum of M events before one can reject the
null hypothesis. This still requires continuous monitoring of the data from
the very start, as M events could appear arbitrarily early. Hence, there is
no logistical advantage of imposing this minimum number. The potential
advantage is instead that it may reduce the time to signal and/or increase
the statistical power of the study. Below, in Section 3.2, it is shown that
both of these can be achieved simultaneously.
3.1 Exact Critical Values
In Table 1 we present the critical values for the maximized SPRT when
requiring a minimum number of events M to signal. When M = 1, we get
the standard maximized SPRT, whose previously calculated critical values[4]
are included for comparison purposes.
The exact critical values are based on numerical calculations using the R
package ’Sequential’. The critical values were calculated in the same manner
as the exact critical values for the Poisson based MaxSPRT[4], with the
modified requirement that the first possible time to signal is at M rather
than 1 event. In brief, first note that the time when the critical value is
reached and the null hypothesis is rejected can only happen at the time when
an event occurs. For any specified critical value CV and maximum sample
size T , it is then possible to calculate alpha, the probability of rejecting the
null, using an iterative approach. Critical values are then obtained through
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Minimum Number of Events Required to Reject the Null
T M=1 2 3 4 6 8 10
1 2.853937 2.366638 1.774218 .. .. .. ..
1.5 2.964971 2.576390 2.150707 1.683209 .. .. ..
2 3.046977 2.689354 2.349679 2.000158 .. .. ..
2.5 3.110419 2.777483 2.474873 2.187328 .. .. ..
3 3.162106 2.849327 2.565320 2.317139 1.766485 .. ..
4 3.245004 2.937410 2.699182 2.498892 2.089473 1.564636 ..
5 3.297183 3.012909 2.803955 2.623668 2.267595 1.936447 ..
6 3.342729 3.082099 2.873904 2.699350 2.406810 2.093835 1.740551
8 3.413782 3.170062 2.985560 2.829259 2.572627 2.337771 2.086032
10 3.467952 3.238009 3.064248 2.921561 2.690586 2.484834 2.281441
12 3.511749 3.290551 3.125253 2.993106 2.781435 2.589388 2.415402
15 3.562591 3.353265 3.199953 3.075613 2.877939 2.711996 2.556634
20 3.628123 3.430141 3.288216 3.176370 2.997792 2.846858 2.717137
25 3.676320 3.487961 3.356677 3.249634 3.081051 2.947270 2.827711
30 3.715764 3.534150 3.406715 3.307135 3.147801 3.019639 2.911222
40 3.774663 3.605056 3.485960 3.391974 3.246619 3.130495 3.030735
50 3.819903 3.657142 3.544826 3.455521 3.317955 3.210428 3.117553
60 3.855755 3.698885 3.590567 3.505220 3.374194 3.271486 3.184196
80 3.910853 3.762474 3.659939 3.580900 3.458087 3.362888 3.284030
100 3.952321 3.810141 3.711993 3.636508 3.520081 3.430065 3.355794
120 3.985577 3.847748 3.753329 3.680584 3.568679 3.482966 3.411235
150 4.025338 3.892715 3.802412 3.732386 3.626150 3.544308 3.476655
200 4.074828 3.948930 3.862762 3.796835 3.696511 3.619825 3.556799
250 4.112234 3.990901 3.908065 3.844847 3.748757 3.675703 3.615513
300 4.142134 4.024153 3.944135 3.882710 3.790143 3.719452 3.661830
400 4.188031 4.075297 3.998950 3.940563 3.852658 3.785930 3.731524
500 4.222632 4.113692 4.040021 3.983778 3.899239 3.835265 3.783126
600 4.250310 4.144317 4.072638 4.018090 3.936175 3.874183 3.823908
800 4.292829 4.191167 4.122559 4.070466 3.992272 3.933364 3.885600
1000 4.324917 4.226412 4.160022 4.109665 4.034210 3.977453 3.931529
Table 1: Exact critical values for the Poisson based maximized SPRT, when a minimum
of M events is required before the null hypothesis can be rejected. T is the upper limit
on the sample size (length of surveillance), expressed in terms of the expected number of
events under the null. The type 1 error is α = 0.05. When T is small and M is large, no
critical value will result in α ≤ 0.05, which is denoted by ’..’
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an iterative mathematical interpolation process, until the desired precision
is obtained. In 3 to 7 iterations, the procedure converges to a precision of
0.00000001. Note that these numerical calculations only have to be done once
for each alpha, T and M. Hence, users do not need to do their own numerical
calculations, as long as they use one of the parameter combinations presented
in Table 1.
The critical values are lower for higher values of M . This is natural.
Since we do not allow the null hypothesis to be rejected based on only a
small number of adverse events, it allows us to be more inclined to reject the
null later on when there are a larger number of events, while still maintaining
the correct overall alpha level. In essence, we are trading the ability to reject
the null with a very small number of events for the ability to more easily
reject the null when there are a medium or large number of events. Note also
that the critical values are higher for larger values of the maximum sample
size T . This is also natural, as there is more multiple testing that needs to
be adjusted for when T is large.
3.2 Statistical Power and Expected Time to Signal
In Table 2 we present statistical power and average time to signal for different
values ofM , the minimum number of events needed to signal. These are exact
calculations, done for different relative risks and for different upper limits T
on the length of surveillance. When T increases, power increases, since the
maximum sample size increases. For fixed T , the power always increases with
increasing M . This is natural, since power increases by default when there
are fewer looks at the data, as there is less multiple testing to adjust for. The
average time to signal may either increase or decrease with increasing values
of M . For example, with T = 20 and a true RR = 2, the average time of
signal is 6.96, 6.62, 6.57 and 6.96 for M = 1, 3, 6 and 10, respectively. For
the same parameters, the statistical power is 0.921, 0.936, 0.948 and 0.957
respectively. Hence, when the true RR = 2 and when T = 20, both power
and the average time to signal is better if we use M = 3 rather than M = 1.
The same is true for M = 6 versus M = 3, but not for M = 10 versus M = 6.
The trade-off between statistical power and average time to signal is not
easily deciphered from Table 2, and it is hence hard to judge which value of
M is best. Since T , the upper limit on the length of surveillance, is the least
important metric, let’s ignore that for the moment, and see what happens to
the average time to signal if we keep both the alpha level and the power fixed.
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Statistical Power Average Time to Signal
T M RR=1.5 2 3 4 10 RR=1.5 2 3 4 10
1 1 0.107 0.185 0.379 0.573 0.987 0.30 0.35 0.39 0.39 0.22
1 3 0.129 0.234 0.466 0.665 0.993 0.59 0.58 0.55 0.51 0.30
2 1 0.130 0.255 0.561 0.799 1.000 0.63 0.75 0.79 0.73 0.24
2 3 0.157 0.315 0.645 0.857 1.000 0.92 0.94 0.89 0.78 0.31
5 1 0.190 0.447 0.876 0.987 1.000 1.82 2.09 1.78 1.22 0.26
5 3 0.224 0.507 0.905 0.991 1.000 2.10 2.17 1.73 1.17 0.31
5 6 0.255 0.559 0.928 0.994 1.000 2.71 2.58 2.05 1.54 0.60
10 1 0.280 0.685 0.989 1.000 1.000 4.02 4.13 2.45 1.35 0.27
10 3 0.321 0.733 0.993 1.000 1.000 4.25 4.07 2.31 1.30 0.32
10 6 0.358 0.770 0.995 1.000 1.000 4.71 4.25 2.50 1.61 0.60
10 10 0.391 0.803 0.996 1.000 1.000 5.67 5.03 3.40 2.50 1.00
20 1 0.450 0.921 1.000 1.000 1.000 8.68 6.96 2.67 1.41 0.28
20 3 0.492 0.936 1.000 1.000 1.000 8.65 6.62 2.53 1.37 0.33
20 6 0.531 0.948 1.000 1.000 1.000 8.92 6.57 2.69 1.65 0.60
20 10 0.562 0.957 1.000 1.000 1.000 9.47 6.96 3.50 2.51 1.00
50 1 0.803 1.000 1.000 1.000 1.000 20.45 8.94 2.82 1.48 0.30
50 3 0.829 1.000 1.000 1.000 1.000 19.82 8.45 2.71 1.45 0.33
50 6 0.847 1.000 1.000 1.000 1.000 19.41 8.24 2.86 1.71 0.60
50 10 0.863 1.000 1.000 1.000 1.000 19.35 8.46 3.59 2.52 1.00
100 1 0.978 1.000 1.000 1.000 1.000 29.93 9.30 2.92 1.53 0.31
100 3 0.982 1.000 1.000 1.000 1.000 28.52 8.87 2.82 1.51 0.34
100 6 0.985 1.000 1.000 1.000 1.000 27.58 8.71 2.97 1.75 0.60
100 10 0.987 1.000 1.000 1.000 1.000 27.04 8.93 3.65 2.53 1.00
200 1 1.000 1.000 1.000 1.000 1.000 33.00 9.62 3.01 1.58 0.32
200 3 1.000 1.000 1.000 1.000 1.000 31.47 9.25 2.93 1.56 0.35
200 6 1.000 1.000 1.000 1.000 1.000 30.47 9.11 3.07 1.78 0.60
200 10 1.000 1.000 1.000 1.000 1.000 29.88 9.33 3.71 2.54 1.00
Table 2: Statistical power and average time to signal, when the null hypothesis is rejected,
for the Poisson based maximized SPRT when a minimum of M events is required before
the null hypothesis can be rejected. T is the upper limit on the sample size (length of
surveillance), expressed in terms of the expected number of events under the null. The
type 1 error is α = 0.05.
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Figure 1: The average time to signal, as a function of statistical power, for
the Poisson based MaxSPRT when a minimum of M events is required before
the null hypothesis can be rejected. The type 1 error is α = 0.05.
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That will make it easier to find a good choice for M , which will depend on
the true relative risk. Figure 1 shows the average time to signal as a function
of statistical power, for different values of M . The lower curves are better,
since the expected time to signal is shorter. Suppose we design the sequential
analysis to have 95 percent power to detect a relative risk of 1.5. We can
then look at the left side of Figure 1 to see the average time to signal for
different true relative risks. We see that for a true relative risk of 1.5, time to
signal is shortest for M = 10. On the other hand, for a true relative risk of 2,
it is shortest for M = 6, for a true relative risk of 3, it is shortest for M = 3
and for a true relative risk of 4, it is shortest for M = 2. On the right side
of Figure 1, we show the expected time to signal when the surveillance has
been designed to attain a certain power for a relative risk of 2. The results
are similar.
When the true relative risk is higher, it is a more serious safety problem,
and hence, it is more important to detect it earlier. So, while there is no
single value of M that is best overall, anywhere in the 3 to 6 range may be
a reasonable choice for M . The cost of this reduced time to signal when the
null is rejected is a slight delay until the surveillance ends when the null is
not rejected.
4 Delayed Start of Surveillance
For logistical or other reasons, it is not always possible to start post-marketing
safety surveillance at the time that the first vaccine or drug is given. If the
delay is short, one could ignore this and pretend that the sequential analyses
started with the first exposed person. One could do this either by starting
to calculate the test statistic at time D or by calculating it retroactively for
all times before D. The former will be conservative, not maintaining the cor-
rect alpha level. The latter will maintain the correct alpha level, but, some
signals will be unnecessarily delayed without a compensatory improvement
in any of the other metrics. A better solution is to use critical values that
take the delayed start of surveillance into account.
4.1 Exact Critical Values
In Table 3 we present exact critical values for the maximized SPRT when
surveillance does not start until the expected number of events under the
10
DT 0 1 2 3 4 6 8 10
1.5 2.964971 1.683208 .. .. .. .. .. ..
2 3.046977 2.000158 .. .. .. .. .. ..
2.5 3.110419 2.187328 1.600544 .. .. .. .. ..
3 3.162106 2.317139 1.766484 .. .. .. .. ..
4 3.245004 2.498892 2.089473 1.842319 .. .. .. ..
5 3.297183 2.545178 2.267595 1.936447 1.611553 .. .. ..
6 3.342729 2.546307 2.406809 2.093835 1.921859 .. .. ..
8 3.413782 2.694074 2.572627 2.337771 2.211199 1.829011 .. ..
10 3.467952 2.799333 2.591675 2.484834 2.298373 2.087405 1.834622 ..
12 3.511749 2.880721 2.683713 2.589388 2.415402 2.254018 1.965660 1.755455
15 3.562591 2.970411 2.794546 2.711996 2.556634 2.347591 2.203782 2.020681
20 3.628123 3.082511 2.918988 2.846635 2.717137 2.542045 2.425671 2.260811
25 3.676320 3.159490 3.011001 2.886783 2.827711 2.668487 2.527763 2.432668
30 3.715764 3.223171 3.080629 2.963485 2.911222 2.765594 2.634068 2.553373
40 3.774663 3.313966 3.186878 3.078748 3.030735 2.903286 2.789967 2.684730
50 3.819903 3.381606 3.261665 3.162197 3.117553 2.999580 2.897811 2.802863
60 3.855755 3.434748 3.320749 3.226113 3.162908 3.051470 2.978063 2.890933
80 3.910853 3.515052 3.407923 3.321868 3.247872 3.151820 3.090356 3.019184
100 3.952321 3.574091 3.472610 3.391377 3.321971 3.232345 3.155596 3.109251
120 3.985577 3.620223 3.523446 3.445695 3.379278 3.294843 3.222053 3.177847
150 4.025338 3.675035 3.583195 3.509028 3.446674 3.367227 3.298671 3.238461
200 4.074828 3.742843 3.655984 3.587079 3.528662 3.454679 3.391821 3.336012
250 4.112234 3.792978 3.710128 3.644349 3.588871 3.518954 3.459256 3.406929
300 4.142134 3.832686 3.752749 3.689355 3.636272 3.568952 3.512138 3.462111
400 4.188031 3.893093 3.785930 3.757574 3.707431 3.644405 3.591092 3.544518
500 4.222632 3.938105 3.835264 3.808087 3.760123 3.700032 3.649189 3.605012
600 4.250310 3.973710 3.874183 3.847892 3.801678 3.743656 3.694832 3.652326
800 4.292829 4.028089 3.933363 3.887512 3.864597 3.809685 3.763627 3.723608
1000 4.324917 4.047191 3.977453 3.931529 3.911308 3.858669 3.814122 3.776275
Table 3: Exact critical values for the Poisson based maximized SPRT, when surveillance
does not start until the sample size is large enough to generate D expected events under
the null hypothesis. T > D is the upper limit on the sample size. The minimum number
of events needed to reject is set to M = 1. The type 1 error is α = 0.05. For some values of
T and D, the critical values are conservative with α < 0.05. These are denoted in italics.
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T D M CVcons αcons CVlib αlib
5 1 1,4 2.545178 0.04587 2.545177 0.05323
10 2 1,4 2.591675 0.04998 2.591674 0.05478
10 4 1,4 2.298373 0.04924 2.298372 0.05379
10 8 1,4 1.834622 0.04373 1.834621 0.05001
15 10 1,4 2.020681 0.04755 2.020680 0.05124
20 3 1,4 2.846635 0.04712 2.846634 0.05001
60 4 1,4 3.162908 0.04922 3.162907 0.05094
60 6 1,4 3.051470 0.04953 3.051469 0.05101
80 8 1,4 3.090356 0.04906 3.090355 0.05023
800 3 1,4 3.887512 0.04992 3.887511 0.05091
1000 1 1,4 4.047191 0.04944 4.047190 0.05094
1000 8 1,4 3.814122 0.04944 3.814121 0.05002
Table 4: Critical values and exact alpha levels for those combinations of T , D and M
for which there does not exist a critical value for α = 0.05. T is the upper limit on the
sample size (length of surveillance), expressed in terms of the expected number of events
under the null. D is the sample size at which the sequential analyses start, also expressed
in terms of the expected number of events under the null. M is the minimum number of
events required to signal. CVcons and CVlib are the conservative and liberal critical values,
respectively, while αcons and αlib are their corresponding alpha levels.
null hypothesis is D, without any requirement on having a minimum umber
of events to signal. When D = 0, we get the standard maximized SPRT,
whose critical values[4] are included for comparison purposes. Note that the
critical values are lower for higher values of D. Since surveillance is not
performed until the sample size have reached D expected counts under the
null, one can afford to use a lower critical value for the remaining time while
still maintaining the same overall alpha level. As before, the critical values
are higher for larger values of T . When D > T , the surveillance would not
start until after the end of surveillance, so those entries are blank in Table 3.
When D = T , there is only one non-sequential analysis performed, so there
are no critical values for a sequential test procedure. Hence, they are also
left blank in the Table.
With a delayed start, there are some values of T and D for which there
is no critical value that gives an alpha level of exactly 0.05. For those com-
binations, denoted with italics, Table 3 presents the critical value that gives
the largest possible alpha less than 0.05. In Table 4, we present the exact
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alpha levels obtained for those scenarios, as well as the α > 0.05 obtained
for a slightly smaller liberal critical value.
The exact critical values are based on numerical calculations done in the
same iterative way as for the original MaxSPRT and the version described in
the previous section. The only difference is that there is an added initial step
where the probabilities are calculated for different number of events at the de-
fined start time D. Open source R functions[25] have been published as part
of the R package ’Sequential’ (cran.r-project.org/web/packages/Sequential/).
4.2 Statistical Power and Timeliness
For a fixed value on the upper limit on the sample size T , the statistical power
of sequential analyses always increases if there are fewer looks at the data,
with the maximum attained when there is only one non-sequential analysis
after all the data has been collected. Hence, for fixed T , a delay in the start
of surveillance always increases power, as can be seen in Table 5. For fixed
T , the average time to signal almost always increases with a delayed start.
The rare exception is when T is very large and the true RR is very small.
For example, for T = 100 and RR = 1.5, the average time to signal is 29.9
without a delayed start, 27.2 with a delayed start of D = 3 and 27.0 with a
delayed start of D = 6. With a longer delay of D = 10, the average time to
signal increases to 27.4.
For fixed T , we saw that there is a trade-off between power and the
time to signal, but in post-market safety surveillance it is usually easy and
inexpensive to increase power by increasing T . Hence, the critical evaluation
is to compare the average time to signal when holding both power and the
alpha level fixed. This is done in Figure 2. When the study is powered for a
relative risk of 2, then the average time to signal is lower when there is less
of a delay in the start of the surveillance, whether the true relative risk is
small or large. When the study is powered for a relative risk of 1.5, we see
the same thing, except when the true relative risk is small. Hence, in terms
of performance, smaller D is always better.
5 Discussion
With the establishment of new near real-time post-market drug and safety
surveillance systems[16, 26, 27, 28, 29], sequential statistical methods will
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Power Average Time to Signal
RR= 1.5 2 3 4 10 1.5 2 3 4 10
T D
5 0 0.190 0.447 0.876 0.987 1.000 1.82 2.09 1.78 1.22 0.26
5 3 0.275 0.595 0.943 0.996 1.000 3.81 3.65 3.30 3.08 3.00
10 0 0.280 0.685 0.989 1.000 1.000 4.02 4.13 2.45 1.35 0.27
10 3 0.377 0.789 0.996 1.000 1.000 5.33 4.84 3.53 3.10 3.00
10 6 0.408 0.819 0.997 1.000 1.000 6.94 6.59 6.07 6.00 6.00
20 0 0.450 0.921 1.000 1.000 1.000 8.68 6.96 2.67 1.41 0.28
20 3 0.543 0.952 1.000 1.000 1.000 9.44 7.06 3.78 3.17 3.00
20 6 0.583 0.963 1.000 1.000 1.000 10.42 8.20 6.15 6.01 6.00
20 10 0.609 0.969 1.000 1.000 1.000 12.33 10.83 10.01 10.00 10.00
50 0 0.803 1.000 1.000 1.000 1.000 20.45 8.94 2.82 1.48 0.30
50 3 0.860 1.000 1.000 1.000 1.000 19.39 8.50 3.85 3.18 3.00
50 6 0.871 1.000 1.000 1.000 1.000 19.65 9.43 6.16 6.01 6.00
50 10 0.885 1.000 1.000 1.000 1.000 20.64 11.82 10.02 10.00 10.00
100 0 0.978 1.000 1.000 1.000 1.000 29.93 9.30 2.92 1.53 0.31
100 3 0.987 1.000 1.000 1.000 1.000 27.16 8.95 3.90 3.18 3.00
100 6 0.988 1.000 1.000 1.000 1.000 26.98 9.97 6.24 6.01 6.00
100 10 0.990 1.000 1.000 1.000 1.000 27.40 12.09 10.02 10.00 10.00
200 0 1.000 1.000 1.000 1.000 1.000 33.00 9.62 3.01 1.58 0.32
200 3 1.000 1.000 1.000 1.000 1.000 30.01 9.35 3.94 3.18 3.00
200 6 1.000 1.000 1.000 1.000 1.000 29.78 10.31 6.26 6.01 6.00
200 10 1.000 1.000 1.000 1.000 1.000 30.16 12.48 10.04 10.00 10.00
Table 5: Statistical power and average time to signal for the Poisson based maximized
SPRT, when the analyses does not start until the sample size is large enough to correspond
to D expected events under the null hypothesis. T is the upper limit on the sample size
(length of surveillance), expressed in terms of the expected number of events under the
null. The minimum number of events required to signal is set to M = 1. The type 1 error
is α = 0.05.
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Figure 2: The average time to signal, as a function of statistical power, for
the Poisson based maximized SPRT, when the analyses does not start until
the sample size is large enough to correspond to D expected events under
the null hypothesis. The type 1 error is α = 0.05.
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become a standard feature of the phramacovigilance landscape. In this paper
we have shown that it is possible to reduce the expected time to signal when
the null is rejected, without loss of statistical power, by requiring a minimum
number of adverse events before generating a statistical signal. This will allow
users to optimize their post-market sequential analyses.
In this paper we calculated the critical values, power and timeliness for
Poisson based continuous sequential analysis with either a minimum events
to signal requirement or when there is delayed start for logistical reasons.
The reported numbers are based on exact numerical calculations rather than
approximate asymptotic calculations or computer simulations. From a math-
ematical and statistical perspective, these are straight forward extensions of
prior work on exact continuous sequential analysis. The importance of the
results are hence from practical public health perspective rather than for any
theoretical statistical advancements.
A key question is which sequential study design to use. There is not
always a simple answer to that question, as the performance of the various
versions depends on the true relative risk, which is unknown. One important
consideration is that the early detection of an adverse event problem is more
important when the relative risk is high, since more patients are affected.
As a rule of thumb, it is reasonable to require a minimum of about M = 3
to 6 adverse events before rejecting the null hypothesis, irrespectively of
whether it is a rare or common adverse event. For those who want a specific
recommendation, we suggest M = 4.
Critical values, statistical power and average time to signal has been
presented for a wide variety of parameter values. This is done so that most
user will not have to perform their own calculations. For those who want to
use other parameter values, critical values, power and expected time to signal
can be calculated using the ’Sequential’ R package that we have developed.
It is possible to combine a delayed start with D > 0 together with a
requirement that there are at least M > 1 events to signal. It does not
always make a difference though. For M = 4, the critical values are the same
as for M = 1, for all values of D ≥ 1. That is because with D = 1 or higher,
one would never signal with less than three events anyhow. Since the critical
values are the same, the statistical power and average time to signal are also
the same. This means that when there is a non-trivial delayed start, there
is not much benefit from also requiring a minimum number events to signal,
but the ’Sequential’ R package has a function for this dual scenario as well.
There is no reason to purposely delay the start of the surveillance until
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there is some minimum sample size D. In the few scenarios for which such
a delay improve the performance, the improvement is not measurably better
than the improvements obtained by using a minimum number of observed
events. Only when it is logistically impossible to start the surveillance at
the very beginning should such sequential analyses be conducted, and then
it is important to do so in order to maximize power, to minimize the time to
signal and to maintain the correct alpha level.
For self-controlled analyses, a binomial version of the MaxSPRT[4] is
used rather than the Poisson version discussed in this paper. For concurrent
matched controls, a flexible exact sequential method is used that allows for
a different number of controls per exposed individuals[30]. By default, these
types of continuous sequential methods will not reject the null hypothesis
until there is a minimum number of events observed. To see this, consider the
case with a 1:1 ratio of exposed to unexposed and and assume that the first
four adverse events all are in the exposed category. Under the null hypothesis,
the probability of this is (1/2)4 = 0.0625, which does not give a low enough
p-value to reject the null hypothesis even in a non-sequential setting. Hence,
the null will never be rejected after only four adverse events, even when there
is no minimum requirement. One could set the minimum number of exposed
events to something higher, and that may be advantageous. If there is a
delayed start for logistical reasons, then it makes sense to take that into
account when calculating the critical value, for these two types of models as
well.
Since the Vaccine Safety Datalink[31] launched the first near real-time
post-marketing vaccine safety surveillance system in 2004[2], continuous se-
quential analysis has been used for a number of vaccines and potential adverse
events[1, 5, 6, 7, 8, 9, 10, 12]. The critical value tables presented in this pa-
per has already been used by the Vaccine Safety Datalink project. As new
near real-time post-market safety surveillance systems are being developed,
it is important to fine-tune and optimize the performance of near-real time
safety surveillance systems[16, 17, 27, 32, 33, 34]. While the improved time
to signal is modest compared to the original version of the Poisson based
MaxSPRT, there is no reason not to use these better designs.
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